{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:18:27Z","timestamp":1787167107336,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,8,22]],"date-time":"2012-08-22T00:00:00Z","timestamp":1345593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s10147-012-0458-9","type":"journal-article","created":{"date-parts":[[2012,8,21]],"date-time":"2012-08-21T01:00:01Z","timestamp":1345510801000},"page":"927-933","source":"Crossref","is-referenced-by-count":45,"title":["Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia"],"prefix":"10.1007","volume":"18","author":[{"given":"Antonio","family":"Ruggiero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palma","family":"Maurizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"De Nisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vendittelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Zuppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Mordente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,22]]},"reference":[{"key":"458_CR1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/pbc.20313","volume":"48","author":"M Rather","year":"2007","unstructured":"Rather M, Carlsen NL, Oxh\u00f8j H (2007) Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 48:663\u2013667","journal-title":"Pediatr Blood Cancer"},{"key":"458_CR2","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","volume":"266","author":"LJ Steinherz","year":"1991","unstructured":"Steinherz LJ, Steinherz PG, Tan CT et al (1991) Cardiac toxicity 4 to 20\u00a0years after completing anthracycline therapy. JAMA 266:1672\u20131677","journal-title":"JAMA"},{"key":"458_CR3","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.ejca.2006.08.005","volume":"42","author":"EC Dalen van","year":"2006","unstructured":"van Dalen EC, van der Pal HJ, Kok WE et al (2006) Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer 42:3191\u20133198","journal-title":"Eur J Cancer"},{"key":"458_CR4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","volume":"22","author":"VB Pai","year":"2000","unstructured":"Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263\u2013302","journal-title":"Drug Saf"},{"key":"458_CR5","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0002-9149(01)01476-X","volume":"87","author":"BW Eidem","year":"2001","unstructured":"Eidem BW, Sapp BG, Suarez CR et al (2001) Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children. Am J Cardiol 87:1120\u20131122","journal-title":"Am J Cardiol"},{"key":"458_CR6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.echo.2005.08.018","volume":"19","author":"M Belham","year":"2006","unstructured":"Belham M, Kruger A, Pritchard C (2006) The Tei index identifies a differential effect on left and right ventricular function with low-dose anthracycline chemotherapy. J Am Soc Echocardiogr 19:206\u2013210","journal-title":"J Am Soc Echocardiogr"},{"key":"458_CR7","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0002-9149(00)01222-4","volume":"86","author":"M Ishii","year":"2000","unstructured":"Ishii M, Tsutsumi T, Himeno W et al (2000) Sequential evaluation of left ventricular myocardial performance in children after anthracycline therapy. Am J Cardiol 86:1279\u20131281","journal-title":"Am J Cardiol"},{"key":"458_CR8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1067\/mje.2001.110586","volume":"14","author":"T Sato","year":"2001","unstructured":"Sato T, Harada K, Tamura M et al (2001) Cardiorespiratory exercise capacity and its relation to a new Doppler index in children previously treated with anthracycline. J Am Soc Echocardiogr 14:256\u2013263","journal-title":"J Am Soc Echocardiogr"},{"key":"458_CR9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/PL00021001","volume":"23","author":"B Ocal","year":"2002","unstructured":"Ocal B, Oguz D, Karademir S et al (2002) Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin-treated patients and its correlation to conventional echo\/Doppler indices. Pediatr Cardiol 23:522\u2013527","journal-title":"Pediatr Cardiol"},{"key":"458_CR10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00392-007-0633-6","volume":"97","author":"F Dodos","year":"2008","unstructured":"Dodos F, Halbsguth T, Erdmann E et al (2008) Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 97:318\u2013326","journal-title":"Clin Res Cardiol"},{"key":"458_CR11","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.1999.17.7.2237","volume":"17","author":"EH Herman","year":"1999","unstructured":"Herman EH, Zhang J, Lipshultz SE et al (1999) Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17:2237\u20132243","journal-title":"J Clin Oncol"},{"key":"458_CR12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa035153","volume":"351","author":"SE Lipshultz","year":"2004","unstructured":"Lipshultz SE, Rifai N, Dalton VM et al (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145\u2013153","journal-title":"N Engl J Med"},{"key":"458_CR13","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1161\/01.CIR.96.8.2641","volume":"96","author":"SE Lipshultz","year":"1997","unstructured":"Lipshultz SE, Rifai N, Sallan SE et al (1997) Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 96:2641\u20132648","journal-title":"Circulation"},{"key":"458_CR14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/08880010802244001","volume":"25","author":"AM Mavinkurve-Groothuis","year":"2008","unstructured":"Mavinkurve-Groothuis AM, Kapusta L, Nir A et al (2008) The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature. Pediatr Hematol Oncol 25:655\u2013664","journal-title":"Pediatr Hematol Oncol"},{"key":"458_CR15","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","volume":"11","author":"SE Lipshultz","year":"2010","unstructured":"Lipshultz SE, Scully RE, Lipsitz SR et al (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950\u2013961","journal-title":"Lancet Oncol"},{"key":"458_CR16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1515\/CCLM.2006.016","volume":"44","author":"S Albers","year":"2006","unstructured":"Albers S, Mir TS, Haddad M et al (2006) N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clin Chem Lab Med 44:80\u201385","journal-title":"Clin Chem Lab Med"},{"key":"458_CR17","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"RM Lang","year":"2005","unstructured":"Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440\u20131463","journal-title":"J Am Soc Echocardiogr"},{"key":"458_CR18","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/PL00021001","volume":"23","author":"B Ocal","year":"2003","unstructured":"Ocal B, Oguz D, Karademir S et al (2003) Myocardial performance index combining systolic and diastolic myocardial performance in doxorubicin-treated patients and its correlation to conventional echo\/Doppler indices. Pediatr Cardiol 23:522\u2013527","journal-title":"Pediatr Cardiol"},{"key":"458_CR19","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869\u20132879","journal-title":"Cancer"},{"key":"458_CR20","first-page":"411","volume":"6","author":"J Wojtacki","year":"2000","unstructured":"Wojtacki J, Lewicka-Nowak E, Le\u015bniewski-Kmak K (2000) Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention\u2014review of the literature. Med Sci Monit 6:411\u2013420","journal-title":"Med Sci Monit"},{"key":"458_CR21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/08880010802016649","volume":"25","author":"A Ruggiero","year":"2008","unstructured":"Ruggiero A, Ridola V, Puma N et al (2008) Anthracycline cardiotoxicity in childhood. Pediatr Hematol Oncol 25:261\u2013281","journal-title":"Pediatr Hematol Oncol"},{"key":"458_CR22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1172\/JCI109642","volume":"65","author":"JH Doroshow","year":"1980","unstructured":"Doroshow JH, Locker GY, Myers CE (1980) Enzymatic defenses of the mouse heart against reactive oxygen metabolites. J Clin Invest 65:128\u2013135","journal-title":"J Clin Invest"},{"key":"458_CR23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-0773.1994.tb00330.x","volume":"75","author":"F Rossi","year":"1994","unstructured":"Rossi F, Filippelli W, Russo S et al (1994) Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances. Pharmacol Toxicol 75:99\u2013107","journal-title":"Pharmacol Toxicol"},{"key":"458_CR24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0301-4622(90)80012-V","volume":"35","author":"E Goormaghtigh","year":"1990","unstructured":"Goormaghtigh E, Huart P, Praet M et al (1990) Structure of the doxorubicin-cardiolipin complex role in mitochondrial toxicity. Biophys Chem 35:247\u2013257","journal-title":"Biophys Chem"},{"key":"458_CR25","first-page":"449","volume":"137","author":"SA Huber","year":"1990","unstructured":"Huber SA (1990) Doxorubicin-induced alterations in cultured myocardial cells stimulate cytolytic T lymphocyte responses. Am J Pathol 137:449\u2013456","journal-title":"Am J Pathol"},{"key":"458_CR26","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","volume":"109","author":"ET Yeh","year":"2004","unstructured":"Yeh ET, Tong AT, Lenihan DJ et al (2004) Cardiovascular complication of cancer therapy: diagnosis, pathogenesis and management. Circulation 109:3122\u20133131","journal-title":"Circulation"},{"key":"458_CR27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00392-007-0469-5","volume":"96","author":"K Kurz","year":"2007","unstructured":"Kurz K, Voelker R, Zdunek D et al (2007) Effect of stress-induced reversible ischemia on serum concentrations of ischemia-modified albumin, natriuretic peptides and placental growth factor. Clin Res Cardiol 96:152\u2013159","journal-title":"Clin Res Cardiol"},{"key":"458_CR28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00392-006-0375-x","volume":"95","author":"M Weber","year":"2006","unstructured":"Weber M, Kleine C, Keil E et al (2006) Release pattern of N-terminal pro B-type natriuretic peptide (NT-proBNP) in acute coronary syndromes. Clin Res Cardiol 95:270\u2013280","journal-title":"Clin Res Cardiol"},{"key":"458_CR29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejheart.2004.03.009","volume":"7","author":"G Daugaard","year":"2005","unstructured":"Daugaard G, Lassen U, Bie P et al (2005) Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 7:87\u201393","journal-title":"Eur J Heart Fail"},{"key":"458_CR30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/hj.1998.v136.89908","volume":"136","author":"T Suzuki","year":"1998","unstructured":"Suzuki T, Hayashi D, Yamazaki T et al (1998) Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 136:362\u2013363","journal-title":"Am Heart J"},{"key":"458_CR31","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.1999.17.7.2237","volume":"17","author":"EH Herman","year":"1999","unstructured":"Herman EH, Zhang J, Lipshultz SE et al (1999) Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17:2237\u20132243","journal-title":"J Clin Oncol"},{"key":"458_CR32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mpo.2950250305","volume":"25","author":"FM Fink","year":"1995","unstructured":"Fink FM, Genser N, Fink C et al (1995) Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med Pediatr Oncol 25:185\u2013189","journal-title":"Med Pediatr Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-012-0458-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-012-0458-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-012-0458-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T20:37:02Z","timestamp":1562099822000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-012-0458-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,22]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1007\/s10147-012-0458-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,22]]}}}